[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100472393":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":37,"locations":45,"responsibleParty":62,"collaborators":18,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":18,"enrollmentInfo":73,"targetDuration":18,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":18,"overallStatus":48,"whyStopped":18,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Imperial College London","OTHER",[8,14,19,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Real time CGM post acute myocardial infarct","EXPERIMENTAL","Real time Dexcom ONE CGM system to be applied for 26 weeks post acute myocardial infarct. Option for participants in this group to continue using rCGM in an open label observational extension phase for a total of 3 years.",[13],"Device: Dexcom ONE Continuous Glucose Monitoring System",{"label":15,"type":16,"description":17,"interventionNames":18},"Blinded CGM post acute myocardial infarct","NO_INTERVENTION","Blinded Dexcom ONE CGM system to be applied for 10 days at recruitment, and then at days 17-23, week 10 and week 24. This will be for the purposes of monitoring glucose only and is not an intervention and is blinded to the participants and the study investigators. CGM measurements will be blinded until the end of the study. Management of diabetes in this cohort as per usual standards of care.",null,{"label":20,"type":16,"description":21,"interventionNames":18},"Blinded CGM historical acute myocardial infarct (>6 months and \u003C10 years ago)","Blinded Dexcom ONE CGM system to be applied for 10 days at recruitment. This will be for the purposes of monitoring glucose only and is not an intervention and is blinded to the participants and the study investigators. Management of diabetes in this cohort as per usual standards of care.",{"label":23,"type":16,"description":24,"interventionNames":18},"Cardiovascular outcomes control group","Age and sex-matched controls from the NIHR Cardiovascular Health Informatics Collaborative.",[26],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":18},"DEVICE","Dexcom ONE Continuous Glucose Monitoring System","The Dexcom ONE is comprised of a sensor, transmitter and display device (receiver and\u002For compatible smart device). The system features a redesigned, one-touch auto-applicator and sleek, discreet transmitter. CGM involves insertion of a small plastic cannula to the subcutaneous tissue of the abdominal skin by members of the study team. The cannula is attached to a small data. The cannula is attached to a small transmitter which is taped to the skin and sends data about interstitial glucose via Bluetooth to a receiver which displays a blood glucose reading. The Dexcom G6 sends glucose readings to a compatible smart device or the Dexcom receiver every 5 minutes.",[9],[32,35],{"name":33,"affiliation":5,"role":34},"Monika Reddy, MBChB, PhD","PRINCIPAL_INVESTIGATOR",{"name":36,"affiliation":5,"role":34},"Jamil Mayet, MBChB, MD",[38,42],{"name":33,"role":39,"phone":40,"phoneExt":18,"email":41},"CONTACT","020 3311 1062","m.reddy@imperial.ac.uk",{"name":43,"role":39,"phone":18,"phoneExt":18,"email":44},"Nick Oliver, MB BS, BSc","nick.oliver@imperial.ac.uk",[46],{"facility":47,"status":48,"city":49,"state":18,"zip":18,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Hammersmith Hospital inpatient cardiology services","RECRUITING","London","United Kingdom","UK",{"type":53,"coordinates":54},"Point",[55,56],-0.12574,51.50853,{"lat":56,"lon":55},[59],{"name":60,"role":39,"phone":18,"phoneExt":18,"email":61},"Harriet Esdaile","h.esdaile@imperial.ac.uk",{"type":63,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100472393","glucose-monitoring-after-acute-myocardial-infarct-in-people-with-diabetes-100472393",false,"NCT05431296","Glucose Monitoring After Acute Myocardial Infarct in People With Diabetes","GLAM","Inclusion Criteria:\n\nFrom the Hammersmith Hospital In-patient Cardiology Services:\n\n* Adults aged \\>18 years\n* Known or newly diagnosed type 2 diabetes\n* Taking one or more oral hypoglycaemic agent, GLP1 receptor analogue and\u002For insulin\n* Admitted to Hammersmith Hospital cardiology inpatient services with ACS\n* Raised blood troponin level on admission\n\nFrom Imperial College Healthcare Trust Diabetes and Cardiology Clinics:\n\n* Adults aged \\>18 years\n* Known type 2 diabetes\n* Previous acute coronary syndrome within the last 10 years but \\> 6 months ago\n* Taking one or more oral hypoglycaemic agent and \u002For GLP1 receptor analogue, and\u002For insulin\n\nExclusion Criteria:\n\nFrom the Hammersmith Hospital In-patient Cardiology Services:\n\n* HbA1c \\\u003C48mmol\u002Fmol\n* People who have previously had bariatric surgery\n* People taking hydroxyurea\n* People who undergo haemodialysis or peritoneal dialysis\n* Unable to participate due to other factors, as assessed by the Chief Investigators\n* Pregnancy as determined by clinical team\n* Known to have a terminal condition or conditions that suggest a life expectancy less than 1 year\n\nFrom Imperial College Healthcare Trust Diabetes and Cardiology Clinics:\n\n* HbA1c \\\u003C48mmol\u002Fmol\n* People who have previously had bariatric surgery\n* People taking hydroxyurea\n* People who undergo haemodialysis or peritoneal dialysis\n* Unable to participate due to other factors, as assessed by the Chief Investigators\n* Pregnancy as determined by clinical team\n* Known to have a terminal condition or conditions that suggest a life expectancy less than 1 year\n* Previous acute coronary syndrome more than 10 years ago or within the last 6 months\n\nWithdrawal criteria\n\n* The subject has a serious event related to the study\n* Investigated initiated discontinuation of study due to participation or equipment concerns\n* Withdrawal of consent","ALL","18 Years",{"count":74,"type":75},160,"ESTIMATED","INTERVENTIONAL",[78],"NA","Glucose monitoring after Acute Myocardial infarct in people with diabetes is a Dexcom funded study that is investigating whether the use of continuous glucose monitors (Dexcom ONE model) in people with type 2 diabetes facilitates time in glycaemic range in the 6 months after an acute myocardial infarction. As an exploratory outcome it will investigate whether time in glycaemic range is associated with changes in mortality and major adverse cardiac events in the 6 months after acute myocardial infarct.",[81,82,83,84],"Type 2 Diabetes","Acute Myocardial Infarction","Acute Myocardial Infarction With ST Elevation","Diabetes Complications","2024-07-02",{"date":87,"type":88},"2024-07-03","ACTUAL",{"date":90,"type":88},"2023-02-07",{"date":92,"type":75},"2025-02",{"name":5,"class":6},1]